Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


202, 2016

Kyprolis effective for some patients that have used Velcade

By |February 2nd, 2016|News, Research|

MedPage Today reported on a new, retrospective study involving Kyprolis over the weekend. It makes my myeloma specialist, Dr. Tricot, look pretty smart for using Kyprolis as part of my three drug post transplant consolidation therapy.

2901, 2016

Cure Magazine searching for myeloma heroes

By |January 29th, 2016|Inspirational, News|

I’m always writing about a new myeloma hero that I’ve met–or someone that we’ve lost. Sounds like Cure Magazine is determined to identify and recognize them. They even use the term, “myeloma hero.”
Nominate Your
Multiple Myeloma Hero Today!
DO YOU KNOW an individual or institution that has gone above and beyond to make a difference in […]

2401, 2016

FDA expands access to Kyprolis. Big news?

By |January 24th, 2016|News, Therapy|

Friday the FDA expanded it’s approval of how and when carfilzomib (Kyprolis) can be used. Trumpets sounded. I counted eleven industry news outlets that led with the story. My reaction? Big yawn.

2201, 2016

We need more open and honest conversations about multiple myeloma

By |January 22nd, 2016|Caregivers, News, RIP, Support, Tips|

One of my pet peeves: when celebrities don’t disclose the type of cancer that they’re battling. They could at least devulge it in their obituary. Most of the rest of us disclose it. Obviously I’ve done so much more. I’m not implying everyone needs to be as open as I am. But come on: inquiring […]

2101, 2016

MMRF 2015 myeloma year in review

By |January 21st, 2016|News, Research, Support|

I’m part of a Cure Talk Radio broadcast in a few hours featuring Multiple Myeloma Research Foundation co-founder, Anne Quinn Young. If you can’t listen live, I’ll pass along a link so you an listen later.

1501, 2016

Maintenance therapy side effects nothing to brush off

By |January 15th, 2016|About Pat, News, Nutrition, Side effects, Tips, Transplants|

I’m part of the club: experiencing side effects caused–in part–by ongoing maintenance therapy.

601, 2016

Wall Street Journal article about myeloma hits a home run

By |January 6th, 2016|About Pat, Caregivers, Inspirational, News, Research, Support|

Monday morning my email inbox lit up. A Wall Street Journal article–both online and in the hard copy edition–about the FDA’s unprecedented approval of three anti-myeloma drugs in less than a month was featured front and center.

401, 2016

Stem cell transplant fallout front and center in 2016 (Part One)

By |January 4th, 2016|About Pat, News, Tips, Transplants|

Euphoria over a myeloma free PET scan doesn’t make everything else OK. I’ve been struggling with post transplant side effects. Like many of you, bumps in the medical insurance road have bubbled up unexpectedly. Still plenty of drama to kick off 2016.

201, 2016

The power of combination therapies

By |January 2nd, 2016|News, Research, Side effects, Therapy|

New checkpoint inhibitor studies combining the experimental drug, Keytruda, with Revlimid, are working in patients who have become refractory to Revlimid.

3012, 2015

Hotel options for April Beach Party event

By |December 30th, 2015|About Pat, News, Support|

It’s hard to believe that we’re only three months away from the 3rd Annual Pat’s Myeloma Beach Party. The event is a “party” in name only; there will be 15 myeloma experts on hand to address topics that last year’s attendees and readers feel are most important to them.

2912, 2015

Key research breakthroughs at ASH

By |December 29th, 2015|News, Research, Therapy|

Did you see the MMRF’s outline of important myeloma related news at ASH this year? Short and to the point.

2612, 2015

Video highlights of my first few days at ASH

By |December 26th, 2015|News, Therapy, Transplants|

Good friend and fellow myeloma survivor, Jenny Ahlstrom, is a lot better at the technical side of blogging than I am. She uses a lot of video on her site. Jenny interviewed me on Sunday at ASH. You can listen to it here:

2212, 2015

Hopeful news about first PD-1 inhibitor

By |December 22nd, 2015|News, Research|

Another exciting, new immunotherapy may be on the horizon: Keytruda

1912, 2015

More financial aid is on the way!

By |December 19th, 2015|News, Support|

This is awesome news; another source of financial assistance for myeloma patients in need.

1812, 2015

An amazing emotional roller coaster ride

By |December 18th, 2015|About Pat, Diagnostics, News, Side effects, Transplants|

I promised to follow up on yesterday’s amazing news. Dr. Tricot reassures me that my tests confirm there isn’t any active myeloma left.

1712, 2015


By |December 17th, 2015|About Pat, News|

Looks like our highly toxic gamble to try a pair of salvage autologous stem cell transplants worked! I’m at the airport getting ready to board a plane to Atlanta on the way home, so no time to post details…

1712, 2015

Inside look at Darzalex (daratumumab)

By |December 17th, 2015|News, Research, Side effects|

Last week I had the opportunity to interview the Senior Director of Clinical Research for Janssen Pharmaceuticals, Dr. Tahamtan Ahmadi, PhD. Janssen is the company that manufacturers newly FDA approved Darzalex (daratumumab). I promised a more detailed follow up and I’m glad to follow through.

1412, 2015

Back to ASH: Ninlaro and Pomalyst combo promising

By |December 14th, 2015|About Pat, News, Research, Transplants|

Before I pass along important information about Takeda’s new oral proteasome inhibitor, Ninlaro (ixazomib), I wanted to share an update about how I’m doing.

812, 2015

More drugs are good, but aren’t enough

By |December 8th, 2015|News, Research|

Data for more than a dozen “new” myeloma drugs was presented at this week’s American Society of Hematology (ASH) meetings here in Orlando. As I described yesterday, several are hopeful crossover drugs; compounds that are already FDA approved for use against other cancers.

812, 2015

Could leukemia and lymphoma drug work for myeloma patients, too?

By |December 8th, 2015|News, Research|

I’m accumulating way too much information for me to process and pass along right away. I’m still waiting on company verified combination data for Darzalex/Pomalyst/dex. I’ll also have updated stats for ongoing elotuzumab and ARRY-520 trials. In the meantime, I interviewed Dr. Thorsten Graef, the Head of Hematology and Global Medical Safety for pharmacyclics, a […]